利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

189 条记录 (耗时 0.044 秒)

    Nitrogen-containing heterocyclic compound
    1.
    发明申请
    Nitrogen-containing heterocyclic compound 审中-公开
    含氮杂环化合物

    公开(公告)号：US20050096322A1

    公开(公告)日：2005-05-05

    申请号：US10505939

    申请日：2003-02-27

    申请人： Susumu Igarashi ,  Ryo Naito ,  Yoshinori Okamoto ,  Noriyuki Kawano ,  Issei Tsukamoto ,  Ippei Sato ,  Makoto Takeuchi ,  Hiroyuki Kanoh ,  Masato Kobori

    发明人： Susumu Igarashi ,  Ryo Naito ,  Yoshinori Okamoto ,  Noriyuki Kawano ,  Issei Tsukamoto ,  Ippei Sato ,  Makoto Takeuchi ,  Hiroyuki Kanoh ,  Masato Kobori

    IPC分类号： A61P19/00 ,  A61P19/08 ,  A61P19/10 ,  A61P43/00 ,  C07D487/04 ,  A61K31/503

    CPC分类号： C07D487/04

    摘要： As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can serve as an excellent prophylactic or therapeutic agent against a metabolic bone disease, whereby establishing the present invention. Thus, the present invention provides a 3,6-disubstituted 1,2,4-triazolo[4,3-b]pyridazine compound or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable carrier, especially a bone-forming agent.

    摘要翻译： 本发明人为了通过促进成骨细胞的功能开发具有促进骨形成刺激作用的治疗剂而作出努力的结果，发现某些含氮杂环化合物表现出强有力的骨形成刺激 对成骨细胞的作用，因此可以作为抗代谢性骨病的优异的预防或治疗剂，由此建立本发明。 因此，本发明提供了3,6-二取代的1,2,4-三唑并[4,3-b]哒嗪化合物或其药学上可接受的盐，以及包含这种化合物和药学上可接受的载体的药物组合物， 特别是骨形成剂。

    Nitrogen-containing heterocyclic compound
    2.
    发明授权
    Nitrogen-containing heterocyclic compound 失效
    含氮杂环化合物

    公开(公告)号：US07173033B2

    公开(公告)日：2007-02-06

    申请号：US11190859

    申请日：2005-07-28

    申请人： Susumu Igarashi ,  Ryo Naito ,  Yoshinori Okamoto ,  Noriyuki Kawano ,  Issei Tsukamoto ,  Ippei Sato ,  Makoto Takeuchi ,  Hiroyuki Kanoh ,  Masato Kobori

    发明人： Susumu Igarashi ,  Ryo Naito ,  Yoshinori Okamoto ,  Noriyuki Kawano ,  Issei Tsukamoto ,  Ippei Sato ,  Makoto Takeuchi ,  Hiroyuki Kanoh ,  Masato Kobori

    IPC分类号： C07D487/04 ,  A61K31/5025 ,  A61P19/08

    CPC分类号： C07D487/04

    摘要： As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can serve as an excellent prophylactic or therapeutic agent against a metabolic bone disease, whereby establishing the present invention.Thus, the present invention provides a 3,6-disubstituted 1,2,4-triazolo[4,3-b]pyridazine compound or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable carrier, especially a bone-forming agent.

    摘要翻译： 本发明人为了通过促进成骨细胞的功能开发具有促进骨形成刺激作用的治疗剂而作出努力的结果，发现某些含氮杂环化合物表现出强有力的骨形成刺激 对成骨细胞的作用，因此可以作为抗代谢性骨病的优异的预防或治疗剂，由此建立本发明。 因此，本发明提供了3,6-二取代的1,2,4-三唑并[4,3-b]哒嗪化合物或其药学上可接受的盐，以及包含这种化合物和药学上可接受的载体的药物组合物， 特别是骨形成剂。

    Pyrazole derivative
    10.
    发明授权
    Pyrazole derivative 失效
    吡唑衍生物

    公开(公告)号：US07247635B2

    公开(公告)日：2007-07-24

    申请号：US11154591

    申请日：2005-06-17

    申请人： Hirokazu Kubota ,  Yasuhiro Yonetoku ,  Keizo Sugasawa ,  Masashi Funatsu ,  Souichirou Kawazoe ,  Akira Toyoshima ,  Yoshinori Okamoto ,  Jun Ishikawa ,  Makoto Takeuchi

    发明人： Hirokazu Kubota ,  Yasuhiro Yonetoku ,  Keizo Sugasawa ,  Masashi Funatsu ,  Souichirou Kawazoe ,  Akira Toyoshima ,  Yoshinori Okamoto ,  Jun Ishikawa ,  Makoto Takeuchi

    IPC分类号： C07D231/12 ,  A61K31/415

    CPC分类号： C07D231/12 ,  C07D231/14 ,  C07D233/56 ,  C07D249/08 ,  C07D401/12 ,  C07D403/12 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14

    摘要： Drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-dependent calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-dependent calcium channel inhibitors containing the above compounds as the active ingredient, (in the formula, each symbol has the following meaning: B: phenylene, a nitrogen-containing, divalent, saturated ring group, or a monocyclic, divalent heteroaromatic ring group which may be substituted with Alk, X: —NR1—CR2R3—, —CR2R3—NR1—, —NR1—SO2—, —SO2—NR1— or —CR4═CR5—, and A: benzene ring which may have one or more substituents; mono-, di- or tricyclic fused heteroaryl which may have one or more substituents; cycloalkyl which may have one or more substituents; a nitrogen-containing, saturated ring group which may have one or more substituents; lower alkenyl which may have one or more substituents; lower alkynyl which may have one or more substituents; or Alk which may have one or more substituents).

    摘要翻译： 药物，特别是具有钙释放依赖性钙通道抑制作用的药物组合物，特别是含有上述化合物作为活性成分的钙释放依赖性钙通道抑制剂的下述通式（I）表示的吡唑衍生物， （在该式中，每个符号具有以下含义：B：亚苯基，含氮，二价饱和环基或可被Alk，X：-NR 1取代的单环，二价杂芳族环基团 其中R 1，R 2，R 3，R 3，R 3，R 3， -NR 2 - ， - SO 2 - ， - SO 2 - ， - SO 2 - ， - SO 2 - ， - SO 2 - 可以具有一个或多个取代基的一个 - 二环或三环稠合杂芳基，其可以具有一个或多个 取代基;可具有一个或多个取代基的环烷基;可具有一个或多个取代基的含氮饱和环基团 ents 可以具有一个或多个取代基的低级烯基; 可以具有一个或多个取代基的低级炔基; 或Alk，其可以具有一个或多个取代基）。